Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.
BACKGROUND:Duchenne muscular dystrophy (DMD) is a lethal, progressive muscle wasting disease caused by a loss of sarcolemmal bound dystrophin, which results in the death of the muscle fibers leading to the gradual depletion of skeletal muscle. There is significant evidence demonstrating that increas...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-05-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3089598?pdf=render |
| _version_ | 1819026250481532928 |
|---|---|
| author | Jonathon M Tinsley Rebecca J Fairclough Richard Storer Fraser J Wilkes Allyson C Potter Sarah E Squire Dave S Powell Anna Cozzoli Roberta F Capogrosso Adam Lambert Francis X Wilson Stephen P Wren Annamaria De Luca Kay E Davies |
| author_facet | Jonathon M Tinsley Rebecca J Fairclough Richard Storer Fraser J Wilkes Allyson C Potter Sarah E Squire Dave S Powell Anna Cozzoli Roberta F Capogrosso Adam Lambert Francis X Wilson Stephen P Wren Annamaria De Luca Kay E Davies |
| author_sort | Jonathon M Tinsley |
| collection | DOAJ |
| description | BACKGROUND:Duchenne muscular dystrophy (DMD) is a lethal, progressive muscle wasting disease caused by a loss of sarcolemmal bound dystrophin, which results in the death of the muscle fibers leading to the gradual depletion of skeletal muscle. There is significant evidence demonstrating that increasing levels of the dystrophin-related protein, utrophin, in mouse models results in sarcolemmal bound utrophin and prevents the muscular dystrophy pathology. The aim of this work was to develop a small molecule which increases the levels of utrophin in muscle and thus has therapeutic potential. METHODOLOGY AND PRINCIPAL FINDINGS:We describe the in vivo activity of SMT C1100; the first orally bioavailable small molecule utrophin upregulator. Once-a-day daily-dosing with SMT C1100 reduces a number of the pathological effects of dystrophin deficiency. Treatment results in reduced pathology, better muscle physiology leading to an increase in overall strength, and an ability to resist fatigue after forced exercise; a surrogate for the six minute walk test currently recommended as the pivotal outcome measure in human trials for DMD. CONCLUSIONS AND SIGNIFICANCE:This study demonstrates proof-of-principle for the use of in vitro screening methods in allowing identification of pharmacological agents for utrophin transcriptional upregulation. The best compound identified, SMT C1100, demonstrated significant disease modifying effects in DMD models. Our data warrant the full evaluation of this compound in clinical trials in DMD patients. |
| first_indexed | 2024-12-21T05:23:35Z |
| format | Article |
| id | doaj.art-f88f93f8b2a047659005a47423959f5b |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T05:23:35Z |
| publishDate | 2011-05-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-f88f93f8b2a047659005a47423959f5b2022-12-21T19:14:46ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-05-0165e1918910.1371/journal.pone.0019189Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.Jonathon M TinsleyRebecca J FaircloughRichard StorerFraser J WilkesAllyson C PotterSarah E SquireDave S PowellAnna CozzoliRoberta F CapogrossoAdam LambertFrancis X WilsonStephen P WrenAnnamaria De LucaKay E DaviesBACKGROUND:Duchenne muscular dystrophy (DMD) is a lethal, progressive muscle wasting disease caused by a loss of sarcolemmal bound dystrophin, which results in the death of the muscle fibers leading to the gradual depletion of skeletal muscle. There is significant evidence demonstrating that increasing levels of the dystrophin-related protein, utrophin, in mouse models results in sarcolemmal bound utrophin and prevents the muscular dystrophy pathology. The aim of this work was to develop a small molecule which increases the levels of utrophin in muscle and thus has therapeutic potential. METHODOLOGY AND PRINCIPAL FINDINGS:We describe the in vivo activity of SMT C1100; the first orally bioavailable small molecule utrophin upregulator. Once-a-day daily-dosing with SMT C1100 reduces a number of the pathological effects of dystrophin deficiency. Treatment results in reduced pathology, better muscle physiology leading to an increase in overall strength, and an ability to resist fatigue after forced exercise; a surrogate for the six minute walk test currently recommended as the pivotal outcome measure in human trials for DMD. CONCLUSIONS AND SIGNIFICANCE:This study demonstrates proof-of-principle for the use of in vitro screening methods in allowing identification of pharmacological agents for utrophin transcriptional upregulation. The best compound identified, SMT C1100, demonstrated significant disease modifying effects in DMD models. Our data warrant the full evaluation of this compound in clinical trials in DMD patients.http://europepmc.org/articles/PMC3089598?pdf=render |
| spellingShingle | Jonathon M Tinsley Rebecca J Fairclough Richard Storer Fraser J Wilkes Allyson C Potter Sarah E Squire Dave S Powell Anna Cozzoli Roberta F Capogrosso Adam Lambert Francis X Wilson Stephen P Wren Annamaria De Luca Kay E Davies Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS ONE |
| title | Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. |
| title_full | Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. |
| title_fullStr | Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. |
| title_full_unstemmed | Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. |
| title_short | Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. |
| title_sort | daily treatment with smtc1100 a novel small molecule utrophin upregulator dramatically reduces the dystrophic symptoms in the mdx mouse |
| url | http://europepmc.org/articles/PMC3089598?pdf=render |
| work_keys_str_mv | AT jonathonmtinsley dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT rebeccajfairclough dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT richardstorer dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT fraserjwilkes dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT allysoncpotter dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT sarahesquire dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT davespowell dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT annacozzoli dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT robertafcapogrosso dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT adamlambert dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT francisxwilson dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT stephenpwren dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT annamariadeluca dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT kayedavies dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse |